Published in Obesity and Diabetes Week, June 12th, 2006
The trial, which is performed at hospitals in Archangelsk and St. Petersburg, Russia, involves 60 patients. Patient treatment and follow-up is expected to continue for approximately 16 weeks, and the data from the study will be reported in the fourth quarter this year.
Diabetic patients often suffer from complicated ulcers due to dysfunctional immune cells. Biotec Pharmacon's concept for treatment of ulcers is based on the...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Obesity and Diabetes Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.